Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Bottom Line: Here, we explored the effect of the HGF/Met signaling pathway and its inhibitors on resistance to lenvatinib, a VEGFR inhibitor.Lenvatinib potently inhibited the growth of HUVECs induced by VEGF alone, but cells induced by VEGF plus HGF showed lenvatinib resistance.This HGF-induced resistance was cancelled when the Met inhibitor, golvatinib, was added with lenvatinib.
Affiliation: Tsukuba Research Laboratory, Eisai Co., Ltd., Tsukuba, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The surfaces of the A2780 xenograft tumors were reddish, but became pale with combination treatment (Fig.4a). We then tested whether the antitumor effects of combined treatment with lenvatinib and golvatinib were associated with inhibition of tumor angiogenesis in human tumor xenograft models. Consistent with our macroscopic observations, immunohistochemical staining of A2780 xenograft tumors, which were excised from mice treated with compound for 7 days, with antibodies against the endothelial cell marker CD31 demonstrated a decrease in endothelial cell staining with combination treatment (Fig.4b,c) compared with the control or with each treatment individually. Combination treatment also decreased cancer cell proliferation and induced apoptosis of cancer cells (Figs4d,e,S4a,b). Combination treatment also resulted in a significant decrease in tumor microvessel density in the SEKI and KP-4 models, which were treated with compound for 4 days (Fig. S4c,d). Consistent with our in vitro findings, these results suggest that the simultaneous inhibition of VEGFR with lenvatinib and inhibition of Met with golvatinib reduced angiogenesis in the HGF- and VEGF-overexpressing xenograft tumors, resulting in antitumor activity.
Affiliation: Tsukuba Research Laboratory, Eisai Co., Ltd., Tsukuba, Japan.